FIND A CLINICAL TRIAL

CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 07-Nov-19
(Boehringer Ingelheim) Gio Tag Extension 1200-0286
GioTag: Real-world data study on sequential therapy with Gi(l)otrif®/ afatinib as first-line treatment followed by osimertinib inpatients with EGFR mutation positive advanced non-small cell lung cancer
 
CANCER TYPE: Cutaneous
LOCATION: Calgary
OPEN DATE: 31-Oct-19
(Incyte) INCMGA 0012-201/PODIUM 201
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (PODIUM 201)
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 09-Oct-19
(Merck) MK-3475-866 / KEYNOTE-866
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 04-Oct-19
(Exelixis) Cosmic 313
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 02-Oct-19
20170543
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 27-Sep-19
D933QC00001
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 25-Sep-19
PCYC-1145-LT
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 18-Sep-19
(CCTG) REC.4 / EA8143
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 12-Sep-19
1948-CL-0101
A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 10-Sep-19
(Janssen) CR108598 / 54767414MMY2065
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 04-Sep-19
(Clovis) CO-338-063 / TRITON 3
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 28-Aug-19
DHA-WIN
Docosahexaenoic acid (DHA) for Women with Breast Cancer in the Neoadjuvant Setting
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 15-Aug-19
AGCT1532
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
CLICK HERE FOR DETAILS
CANCER TYPE: Sarcoma
LOCATION: Edmonton
OPEN DATE: 01-Aug-19
DCC-2618-03-002
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC- 2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 25-Jul-19
SCH ACCL1333 BMS CV185-155
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 03-Jul-19
MK3475-630
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 03-Jul-19
(Celgene) BB2121-MM-003
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 Versus Daratumumab (DARA) in Combination with Pomalidomide (POM) and Low-dose Dexamethasone (dex) (DPd) or Daratumumab (DARA) in Combination with Bortezomib (BTZ) and Low-dose Dexamethasone (dex) (Dvd) or Ixazomib (IXA) in Combination with Lenalidomide (LEN) and Low-dose Dexamethasone (dex) (IRd) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 02-Jul-19
DREAM
Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 02-Jul-19
MK 3475-689
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
CLICK HERE FOR DETAILS
CANCER TYPE: Neuroendocrine
LOCATION: Calgary
OPEN DATE: 28-Jun-19
(Exelixis) XL184-311/COSMIC-311
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 28-Jun-19
(GSK) 205207 DREAMM 4
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 28-Jun-19
Improving Radiotherapy Setup In Rectal Cancer. (SIRC)
To evaluate pelvic stability and patient comfort during setup for external-beam radiation therapy in rectal cancer patients
 
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Jun-19
BI1381-0009
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 24-Jun-19
Pfizer B1761031 (1012856) AML Mylotarg Study
A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARGTM) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 21-Jun-19
MCRN007
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 17-Jun-19
CA 021 002
A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 17-Jun-19
MK-7902-007
A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 05-Jun-19
(Clovis) CO-338-087 / GOG-3020 / ENGOT-ov45/NCRI/ATHENA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 05-Jun-19
Headstart
Newly Diagnosed Children (Less than 10 years old) with Medulloblastoma and other Central Nervous System Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-ablative chemotherapy with autologous hematopoietic progenitor cell rescue
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 04-Jun-19
(Kartos Therapeutics, Inc.) KRT-232-102
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 31-May-19
(AstraZeneca) D933SC00001 / NILE
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 31-May-19
MK 3475-756
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 31-May-19
(Kartos Therapeutics Inc.) KRT-232-101
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PVMF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 23-May-19
CLEEO11012301C
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 23-May-19
CC-95251-ST-001
A Phase 1, Open-Label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPa, Alone and in Combination with Cetuximab in Subjects with Advanced Solid Cancers
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 14-May-19
(Princess Margaret Cancer Centre) 18-5353 / VALUE
Achieving Value in Cancer Diagnostics: blood versus tissue molecular profiling - a prospective Canadian study (VALUE)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 14-May-19
(Roche) BO40747
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 10-May-19
(AstraZeneca) D5084C00007 / SAVANNAH
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 10-May-19
(Celgene) ACE-536-MDS-002 / COMMANDS
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 08-May-19
(Acerta Pharma BV) ACE-CL-311 / D8221C00001
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemo immunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 08-May-19
(CCTG) CRC.8/ EA2165
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Calgary
OPEN DATE: 07-May-19
(Ayala) AL-ACC-01 / ACCURACY
A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 03-May-19
SGNTV-001
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 03-May-19
NRG-GU006
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 02-May-19
GSK205801
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 02-May-19
ALK 4230-A101
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 22-Apr-19
(Astellas) 8951-CL-0302 / GLOW
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Sarcoma
LOCATION: Edmonton
OPEN DATE: 05-Apr-19
KCP-330-020
A Phase 2-3, multicenter, randomized, doubleblind study of Selinexor (kpt-330) versus placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLS)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 05-Apr-19
IIT-UNSCARRed
A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab with Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 19-Mar-19
OZM-088
Phase I/II of Durvalumab (medi4736) + Tremelimumab + stereotactic body radiotherapy for metastatic head and neck carcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 04-Mar-19
NP40126
A Phase 1B Study Evaluating RO7082859 in Combination with Rituximab (R) or Obinutuzumab (G) plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants with Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants with Untreated Diffuse Large B Cell Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 28-Feb-19
(Daiichi Sankyo Inc.) DS8201-A-U302
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 27-Feb-19
(BCCA) PanGen / H16-00291
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis (PanGen)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Feb-19
ACT15377
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Feb-19
CA 209 848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 26-Feb-19
CA 045 001
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 25-Feb-19
CA027-002
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 20-Feb-19
8374-CL-0101
A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 19-Feb-19
SYD985
A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-Drug Conjugate SYD985 to Physician’s Choice in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 06-Feb-19
D933RC00001
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 31-Jan-19
CA 209 9DX
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 29-Jan-19
AHEP1531
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 28-Jan-19
56021927PCR2032
An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 15-Jan-19
MK3475-716
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 24-Dec-18
ReRAD QOL
Health Related Quality of Life and Symptom Assessment in Patients Diagnosed with DIPG and their Caregivers
 
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 21-Dec-18
FINE ART
Randomized Trial of Unilateral vs Bilateral Neck Irradiation in Head and Neck Cancer Patients Treated with Primary Surgery
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 07-Dec-18
CCTG MAC 19
A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 27-Nov-18
SPI-POZ-202
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 27-Nov-18
(CCTG) MA.39 / TAILOR RT
Tailor RT: A randomized trial of regional radiotherapy in Biomarker low risk node positive breast cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Cutaneous
LOCATION: Calgary
OPEN DATE: 23-Nov-18
(Novartis) CDRB436F2410
COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 21-Nov-18
(AMGEN) 20150161
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 08-Nov-18
8951- CL-0301
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 07-Nov-18
CCTG HN.9
Randomized phase ii study of cisplatin plus radiotherapy versus Durvalumab plus radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by adjuvant Tremelimumab and Durvalumab in intermediate risk hpv-positive Locoregionally advanced oropharyngeal squamous cell Cancer (LA-OSCC)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 25-Oct-18
ReRAD
Tumour Type Brain Tumour: DIPG - A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 22-Oct-18
CLEE011A2404 (LEEOMIC™)
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 22-Oct-18
(Sunnybrook Research Institute) 0891 / SPIREL
Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide administered with Pembrolizumab in Patients with persistent or Recurrent/refractory Diffuse Large B-Cell Lymphoma (DLBCL) (SPiReL)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 16-Oct-18
BGB-3111-212
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 26-Sep-18
MOR208C204
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND
CLICK HERE FOR DETAILS
CANCER TYPE: Neurology
LOCATION: Calgary
OPEN DATE: 25-Sep-18
(CCTG) CE.7
A Phase III Trial of Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 24-Sep-18
NRG-GU005 / HYPORT
Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Sep-18
IIT Imatinib-CCI-PH1-01
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodum Iodide Symporter Function and Sensitivity to Radioiodin Treatment in Metastatic Thyroid Cancer Patients
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 17-Sep-18
CA 018-003
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno- ONcology Study in Participants with Advanced Gastric Cancer (FRACTIONGastric Cancer)
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 05-Sep-18
(ImmunoVaccine) ONC-DPX-Survivac-06
A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 30-Aug-18
CPI-0610
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis). Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 17-Aug-18
Bayer 18594
An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and/or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas (Part B only)
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumor Group
LOCATION: Calgary
OPEN DATE: 31-Jul-18
(Idera) 2125-MEL-301
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with PD 1 Refractory Melanoma
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 31-Jul-18
(AHS) MK3475-418 P-CUP
A Multi-Centre, Single Arm Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients with Poor Prognosis Carcinoma of the Unknown Primary Site
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 30-Jul-18
(CUOG) PRIME
PRIME (CUOG): A Randomized Phase 3 Trial of Metformin in Patient Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 19-Jul-18
REFMAL485 BI1381.2
An open label, Phase I dose-finding study of BI 754111 in combination with BI 754091 in patients with advanced solid cancers and of BI 754111 monotherapy with subsequent combination with BI 754091 i n patients with follicular lymphoma, followed by an expansion cohort at the RPIID of the combination in patients with non-small cell lung cancer
 
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 14-Jun-18
KEYNOTE-651
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 28-May-18
(Regeneron) R2810-ONC-1676
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 24-May-18
(Celgene) CC-92480-MM-001
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 08-May-18
(AstraZeneca) XD5336C00001 234970 / VIOLETTE
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 01-May-18
CO40016 (IPATunity)
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor–Positive, HER2-Negative Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 26-Apr-18
R2810-ONC-1620
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 26-Apr-18
CCTG IND 234
Prostate cancer biomarker enrichment and treatment Selection (pc-bets) study.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 20-Apr-18
ALTE16C1
Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 11-Apr-18
CCTG MAC.21
A Randomized Phase III Double Blind Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer Aspirin for Breast Cancer Study: The ACB Trial
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 10-Apr-18
CCTG IND.223
A Phase II study of Palbociclib, a cdk4/6 inhibitor, in patients with Metastatic castration-resistant prostate cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 04-Apr-18
(Basilea) DZB-CS-301
A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 20-Mar-18
AZ D6185C00001
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Mar-18
CV202-103
A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 08-Mar-18
APEC14B1
Tumour Type All Cancer Types - Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Study
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 08-Mar-18
(Horizon Health Network) The M4 Study
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 28-Feb-18
(Abbvie) M15-654
A Phase 1/2, Multicenter, Open-Label Dose-Escalation and Blinded Expansion Study of Venetoclax, Daratumumab and Dexamethasone Combination Therapy in Subjects with Relapsed or Refractory Multiple Myeloma
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 23-Feb-18
ALTE15N2
Late Effects After High-Risk Neuroblastoma (LEARHN) Study
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 09-Feb-18
MK 4280-001-2003
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 07-Feb-18
LATENT
A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab with Valproic Acid for the Treatment of Virus-associated Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 02-Feb-18
AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
 
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Jan-18
Debio1143-NSCLC-105
A Phase-1b Dose-Finding Study of the SMAC Mimetic Debio 1143 when Given in Combination with the anti-PD-L1 Antibody Avelumab to Patients with Advanced Solid Malignancies and, in an Expansion Cohort, to Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) after Platinum-Based Therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 15-Jan-18
(AbbVie) P16-489 DEVOTE
Post-marketing observational study (PMOS) to describe the management and the use of healthcare resources in patients with chronic lymphocytic leukemia (CLL) initiating venetoclax in routine clinical practice (DEVOTE)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 08-Jan-18
TINI
Total Therapy for Infants with Acute Lymphoblastic Leukemia (ALL) I (IND 127, 270)
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 20-Dec-17
BO29554
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 19-Dec-17
Bayer 15834
Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 29-Nov-17
(AstraZeneca) D5160C00006 / TATTON
A Multi-arm, Phase Ib, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have Progressed Following Therapy with an EGFR TKI (TATTON)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 24-Nov-17
Astellas 2215-CL-0201 LaceWing
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib),Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Neurology
LOCATION: Calgary
OPEN DATE: 13-Nov-17
(Orbus) OT-15-001 / STELLAR
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 08-Nov-17
(CCTG) ALC.4
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumor Group
LOCATION: Calgary
OPEN DATE: 17-Oct-17
(Astex) ASTX660-01
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 26-Sep-17
(Amgen) 20160275 / CANDOR
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 26-Sep-17
H3B-6527-G000-101
An Open-Label Multicenter Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 22-Aug-17
(Clovis) CO-338-043 / ARIEL4
A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 17-Jul-17
ESPS-001
A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 (LY) as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 10-Jul-17
(Tesaro) 4010-01-001 / GARNET
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 22-Jun-17
ACE-LY-308
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 14-Jun-17
(SHSC) OZM-065
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 12-Jun-17
(UHN) OZM-058
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 09-Jun-17
PROfound
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 08-Jun-17
MDV3800-13
A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 19-May-17
MK 3475-365-0102
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 08-May-17
CA 209 490
A prospective study on quality of survival using the Global melanoma research network in Canada
 
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 27-Apr-17
AEWS1221
Tumour Type Metastatic Ewing Sarcoma -Type A Phase III evaluating the Addition of the IGF-1R Antibody Ganitumab to Multiagent Chemotherapy for patient with Newly Diagnosed Metastatic Ewing Sarcoma
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 21-Mar-17
STOP-NSCLC
Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A randomized phase II trial
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 17-Mar-17
(CCTG) IND.227
A Phase II Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 16-Mar-17
OZM-063
OZM-063 A Phase II, Open-Labeled, Multicenter, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naive Children with Unresectable or Progressive Low Grade Glioma (LGG)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 16-Feb-17
CCTG ME 13
A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 23-Dec-16
ACE Study
Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 17-Nov-16
Stemline SL-401-0314
SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 17-Nov-16
(Novartis) CRAD001YCA09 TreatER+ight
Treat ER+ight: Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy ± Targeted Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Neurology
LOCATION: Calgary
OPEN DATE: 22-Sep-16
(CCTG) CEC.6
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 26-Jul-16
NCIC HE.1
A Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 21-Jul-16
CPI-444-001
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 29-Jun-16
IIT-RATIO
Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects with Previously Untreated, Locally Advanced or Metastatic Melanoma
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Calgary
OPEN DATE: 06-Jun-16
(Amgen) 20120139
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 12-May-16
CA 017 003
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 04-Apr-16
NRG - BR002
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Calgary
OPEN DATE: 29-Feb-16
NRG - HN001
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 22-Feb-16
(AHS) OZM-064/STARC
Phase 2 Trial of Rosuvastatin (Crestor®) Combined With Standard Chemoradiation Therapy in the Treatment of High-Risk Locally Advanced Rectal Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 02-Feb-16
NRG - BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumor Group
LOCATION: Calgary
OPEN DATE: 14-Oct-15
RTOG 1112
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 11-Sep-15
(Karyopharm) KCP-330-017 / STOMP
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 17-Aug-15
NCIC MA-32D
Change in mammographic density with metformin use: a Companion study to NCIC study MA.32
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 30-Jul-15
(SHSC) OZM-053
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 27-Jul-15
ANBL1232
Tumour Type Neuroblastoma - Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non High Risk Neuroblastoma
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 03-Jun-15
OCOG-2013-LUSTRE
A Randomized Trial of Medically-Inoperable Stage I Non-Small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy (LUSTRE)
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 22-May-15
RTOG 1216
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 05-May-15
(CCTG) LY.17
A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Blood and Marrow Transplant
LOCATION: Calgary
OPEN DATE: 14-Apr-15
(AHS) HDM-Gem-HDT-ASCT-Shafey GEMHDM2014
Infusional Gemcitabine and High-dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 19-Mar-15
(CCTG) BR.31
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 04-Dec-14
RTOG 1304
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. (NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 20-Nov-14
ACNS0831
Tumour Type Brain Tumour: Ependymoma - Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
CLICK HERE FOR DETAILS
CANCER TYPE: Neurology
LOCATION: Calgary
OPEN DATE: 26-May-14
(RI MUHC) McG 1132
A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter
CLICK HERE FOR DETAILS
CANCER TYPE: Neuroendocrine
LOCATION: Edmonton
OPEN DATE: 29-Apr-14
TX-LUT-001
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours (NAP)
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 12-Nov-13
Deep Inspirational Breath Hold Study
A Cohort Study Assessing Cardiac Function with MRI in Left-Sided Breast Cancer Patients Treated with Deep Inspiration Breath-Hold (DIBH) Technique to Improve Cardiac Sparing during Adjuvant Radiotherapy
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 06-May-13
AALL1131
Tumour Type ALL - A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517)
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 12-Feb-13
(CCTG) CX.5 / SHAPE
A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-Risk Early Stage Cervical Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 26-Sep-12
RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 11-Oct-11
DX-CPERT-001
A Phase I Study of Cyclotron -produced Tc-99m Pertechnetate (CPERT) in Patients with Thyroid Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 10-May-11
Seed Movement
Seed movement in permanent prostate brachytherapy implants: Clinical measurement and dosimetric consequences.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 11-Feb-11
RTOG 1008
A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 15-Jul-10
(CCTG) CO.21 / CHALLENGE
A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 16-Dec-08
DX-FLT-002
A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-deoxy-3'-L-fluorothymidine (18F-FLT) in Patients with Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, or Pancreas, and with Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma (DX-FLT-002)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 30-Nov-08
CS-FAZ-005
A Pilot Study of the Role of 18F-FAZA in Combination with FluGlucoScan® Injection PET Scans in Assessing Early Functional Response in Patients with Inoperable Non-Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy. (CS-FAZ-005)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 11-Dec-07
DX-FLU-001
An Observational Pilot Study of 18F Sodium Fluoride Whole Body Scans in Patients for whom 99mTc Bone Scans Would Normally be Indicated
CLICK HERE FOR DETAILS
CANCER TYPE: Blood and Marrow Transplant
LOCATION: Calgary
OPEN DATE: 04-Apr-07
(AHS) Allergy&HCT E20668
Curability and Transferability of Allergic Disease with Allogeneic Hematopoietic Cell Transplantation
 
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 14-Nov-06
DX-FLT-001
An Imaging Pilot Study of 18F-fluoro-3’-deoxy-3’-L-fluorothymidine (18F-FLT) in Patients with Locally Advanced or Metastatic Pancreatic Cancer who will be Treated with Gemcitabine (DX-FLT-001)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 01-May-06
DX-FAZ-001
A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-18F-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA) in Patients with Known Squamous Cell Carcinoma of the Head & Neck, Small Cell & Non-Small Cell Carcinoma of the Lung, Lymphoma or Glioblastoma Multiforme. (DX-FAZ-001)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 02-Jan-06
AREN03B2
Renal tumors classification, biology and banking study
CLICK HERE FOR DETAILS
CANCER TYPE: Blood and Marrow Transplant
LOCATION: Calgary
OPEN DATE: 19-May-05
(AHS) Immune Reconstitution Study / IRS
Immunity of Hematopoietic Cell Transplant Recipients
 
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 05-May-05
TSX
Thymidylate Synthase Polymorphisms as a predictor of toxicity to Capecitabine based adjuvant chemotherapy in colon cancer treatment
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 21-May-04
ALTE03N1
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 29-Mar-01
ANBL00B1
Tumour Type Neuroblastoma - Neuroblastoma Classification Biology Studies
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 17-Aug-00
RTOG 9910
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: N/A
(UHN) PBExRCT
A Preference-Based Trial of Two Exercise Delivery Methods in Men With PC on ADT
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
AALL08B1
Tumour Type ALL - Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
ACNS1123
Tumour Type Brain Tumour: Germ Cell - Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumours (CNS GCT)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
AHEP0731
Tumour Type Liver: Hepatoblastoma - Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
ALTE07C1
Tumour Type All Types - Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
ALTE11C2
Tumour Type Survivors of Leukemia, Lymphoma and Osteosarcoma -Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
SJMB12
Tumour Type Brain Tumour: Medulloblastoma - A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
TOPAZ
Tumour Type Recurrent Solid and Brain Tumours - A Phase 1 and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent and Refractory Solid Tumors including CNS Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
POE14-01
Tumour Type Recurrent Solid Tumours and Leukemias A Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Recurrent and Refractory Solid Tumors and Leukemias
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
POE16-01
Tumour Type Recurrent Solid or Hematologic Cancers - A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
ACCL1331
Tumour Type ALL and non-Hodgkin lymphoma - A phase III Randomized, Open La el, Multi-Center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention.
 
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: N/A
OZM-063
Tumour Type Brain Tumour: Low Grade Glioma - OZM-063 A Phase II, Open-Labeled, Multicenter, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naive Children with Unresectable or Progressive Low Grade Glioa (LGG)